Analysts have been eager to weigh in on the Healthcare sector with new ratings on Teladoc (TDOC – Research Report), Instil Bio (TIL – Research Report) and Regeneron (REGN – Research Report).
Teladoc (TDOC)
In a report released yesterday, Michael Cherny from Leerink Partners maintained a Hold rating on Teladoc, with a price target of $17.00. The company’s shares closed last Thursday at $14.60, close to its 52-week low of $13.59.
According to TipRanks.com, Cherny is a 4-star analyst with an average return of
Currently, the analyst consensus on Teladoc is a Moderate Buy with an average price target of $20.56, implying a 39.9% upside from current levels. In a report issued on April 5, Deutsche Bank also maintained a Hold rating on the stock with a $18.00 price target.
See today’s best-performing stocks on TipRanks >>
Instil Bio (TIL)
In a report released today, Kelly Shi from Jefferies downgraded Instil Bio to Hold, with a price target of $11.00. The company’s shares closed last Thursday at $11.06.
According to TipRanks.com, Shi is a 1-star analyst with an average return of
Currently, the analyst consensus on Instil Bio is a Moderate Buy with an average price target of $27.67.
Regeneron (REGN)
In a report issued on April 10, David Risinger from Leerink Partners maintained a Buy rating on Regeneron. The company’s shares closed last Thursday at $920.32.
According to TipRanks.com, Risinger is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Regeneron with a $1041.61 average price target, representing a 12.2% upside. In a report issued on March 26, Truist Financial also maintained a Buy rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on TDOC:
- Cathie Wood’s ARK Investment bought 600K shares of Teladoc today
- House eyes extension of pandemic-era Medicare telehealth benefits, Axios reports
- Cathie Wood’s ARK Investment bought 97K shares of Teladoc today
- Teladoc Health Welcomes Mala Murthy as New CEO
- Teladoc Stock (NYSE:TDOC): No Need to Risk Your Financial Health
